GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2007

Kirin and Astellas Partner to Develop Immunosuppressive Mab

  • Kirin Brewery Company and Astellas Pharma will exclusively partner in developing and marketing a fully human anti-CD40 antagonistic Mab worldwide.

    Kirin discovered this CD40 antagonistic Mab and reports that it has shown strong immunosuppressive activity in preclinical studies.

    Under the terms of the license and collaborative R&D agreement, Kirin will receive an upfront payment as well as milestone payments. The companies will share the R&D costs. Astellas has the right to sell the product, and Kirin has the right to co-promote it, both on a worldwide basis.  The companies will share the profits on worldwide sales. Kirin, however, retains co-marketing rights in Japan, and each party will pay the other a royalty instead of profit sharing.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?